Insights from 2024 ASCO® GI Annual Meeting
ASCO® GI 2024 Insights: "LIBRETTO-001 Study - Durable Efficacy of Selpercatinib in Patients With RET Fusion+ Solid Tumors (Focus on GI Tumors)"
By
Insights from 2024 ASCO® GI Annual Meeting
FEATURING
Vivek Subbiah
By
Insights from 2024 ASCO® GI Annual Meeting
FEATURING
Vivek Subbiah
Login to view comments.
Click here to Login